Navigation Links
Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore
Date:10/15/2007

New Treatment Could Benefit Millions Who Suffer From Condition

NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 sites around the world joining in the study.

Medicated, drug-coated stents have been used with great success for the past several years in treating coronary artery disease.

PAD affects more than 10 million Americans, according to the Peripheral Arterial Disease (P.A.D.) Coalition. The disease restricts circulation in blood vessels that lead from the heart to other areas of the body, such as the legs and feet. Often undiagnosed, PAD results in pain when walking and can lead to gangrene and amputation. It also may signal an increased risk for coronary arterial disease and other related circulatory conditions.

"This is an exciting trial since it is the first evaluation of a drug- eluting stent in blood vessels outside the heart," said Evan Lipsitz, MD, chief of Vascular Surgery at Montefiore and principal investigator of the study. "Combining a stent designed to hold blood vessels open to allow blood to flow freely through the vessel, with a medication used to prevent renarrowing, may reduce the development of scar tissue, the primary cause of the stent failure, in the months following balloon angioplasty in leg arteries.

This helps eliminate the need for more invasive treatment, such as bypass surgery," Dr. Lipsitz said.

The stent is coated with paclitaxel, a drug derived from the Pacific yew tree that has been used successfully to reduce the risk of renarrowing of arteries.

The trial is designed to determine the safety and effectiveness of the Zilver(R) PTXTM drug-eluting stent in treating blockages in the femoropoliteal artery, the major artery in the thigh.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, encompasses 125 years of innovative medical "firsts," pioneering clinical research, dedicated community service and ground-breaking social activism.

A full-service, integrated delivery system caring for patients from New York, Westchester County and beyond, Montefiore is a 1,122-bed medical center that includes three hospitals: the Henry and Lucy Moses Division, the Jack D. Weiler Hospital and The Children's Hospital at Montefiore; a large home healthcare agency; the first and largest school health program in the U.S.; a 21-site medical group practice integrated throughout the Bronx and Westchester; and a care management organization providing services to 179,000 health plan members.

The medical center is ranked by the prestigious Leapfrog Group among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology

Montefiore's distinguished centers of excellence include cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children's health, women's health, obesity, diabetes, surgery and the surgical subspecialties. Montefiore is a leader in the treatment of headaches, cough and sleep disorders, geriatrics and geriatric psychiatry, neurology and neurosurgery, bioethics, adolescent and family medicine, HIV/AIDS and social medicine, among many other specialties.


'/>"/>
SOURCE Montefiore Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
5. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
6. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
7. REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis
8. Appendicitis: Evolving Tools to Diagnose a Classic Disease
9. Non-Invasive Diagnostic Tests for Celiac Disease
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:3/24/2017)... 2017 ShangPharma, a leading life ... drug development and discovery services, technology, and ... announced today the intent for a strategic ... consolidating the Contract Research Organizations (CRO) and ... These entities include ChemPartner Shanghai, ChemPartner Fengxian, ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to ... global medical cannabis market will reach a value of USD 55.8 billion ... for the new growing industry. By the end of 2016, 28 states ... medical cannabis. More conservative states like Arkansas and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) has named ... in their 12th year, are among the most prestigious in radiology marketing because a ... were retooled to recognize achievements in both large budget (over $5,000) and small budget ...
(Date:3/24/2017)... San Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... a new clinic which can be found at 9618 Huebner Road. The clinic is ... Thobaben, PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
Breaking Medicine News(10 mins):